Is this the outcome people expected, not least after almost five years? It makes the sudden urgency that so many now demand very odd. Given that the current trajectory means no change for the vast majority of new therapies, why the urgency?
Helpful evidence of how the review is landing on outcomes to potentially benefit a few 'Unicorns'
June 1, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Advent moves to acquire majority stake in NZCR Group
August 21, 2026 - -
Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma
August 21, 2026 - - Latest News -
Biogen bolsters leadership ranks as it sharpens focus on patient access and innovation
August 21, 2026 - - Latest News -
Opportunity #5 - From the hardest thing to secure to the easiest thing to get right
August 21, 2026 - - Latest News -
Rare autoimmune diseases impose a $1.2 billion annual burden on Australians
August 20, 2026 - - Latest News -
New Zealand researchers honoured for work tackling superbugs and blood cancer
August 20, 2026 - - Latest News -
Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm
August 20, 2026 - - Latest News

